AKT1 and colorectal cancer: Given that the prevalence of APC mutations is shown to be lower in BRAF mutated colorectal cancers, alternative modes of pathway activation are at play and may involve inhibition of kinase GSK3 through PI3K/AKT signaling [32,33].